Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

November 15, 2007 (Vol. 27, No. 20)

Letter to the Editor: What About Tysabri as an MS Treatment?

A reader takes umbrage with a GEN article on therapies for this disease.

  • Dear Editor, I find it incomprehensible that Melissa Elder, in her review of existing and pending treatments for MS (“Four Therapies Dominate MS Treatment,” October 1, 2007 GEN, pg. 16), simply ignores the existence of Tysabri (natalizumab), a treatment approved for relapsing forms of MS in the U.S. and ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.